Eliot Forster, F-star CEO (Rachel Kiki for Endpoints News)

F-star gets down to the wire with $161M sale to Chi­nese buy­er as na­tion­al se­cu­ri­ty con­cerns linger

With the clock tick­ing on F-star Ther­a­peu­tics’ takeover by a Chi­nese buy­er, the com­pa­nies are still scram­bling to re­move a hold on the deal from the US gov­ern­ment’s Com­mit­tee on For­eign In­vest­ment in the Unit­ed States.

F-star and in­voX Phar­ma said they are “ac­tive­ly ne­go­ti­at­ing” with CFIUS “about the terms of a mit­i­ga­tion agree­ment to ad­dress CFIUS’s con­cerns re­gard­ing po­ten­tial na­tion­al se­cu­ri­ty risks posed by the trans­ac­tion.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.